BLCO
HealthcareBausch + Lomb Corporation
$16.80
+$0.22 (+1.33%)
Jan 5, 2026
Price History (1Y)
Analysis
Bausch + Lomb Corporation is a leading company in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $5.95 billion, the company operates on a significant scale, employing 13,500 individuals worldwide. Financially, Bausch + Lomb has reported mixed results. The company's profitability metrics reveal a gross margin of 59.4%, operating margin of 6.2%, and profit margin of -6.1%. This indicates a challenging earnings environment, with net income totaling -$305 million over the trailing twelve months. On the other hand, the company's balance sheet shows $310 million in cash, while debt stands at $4.95 billion, resulting in a debt-to-equity ratio of 76.15. In terms of valuation, Bausch + Lomb's forward price-to-earnings ratio is 21.47, and its enterprise value to earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio is 19.45. The company has reported revenue growth of 7.1% year-over-year, but its earnings growth rate is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Visit website →Key Statistics
- Market Cap
- $5.95B
- P/E Ratio
- N/A
- 52-Week High
- $18.34
- 52-Week Low
- $10.45
- Avg Volume
- 438.33K
- Beta
- 0.61
Company Info
- Industry
- Medical Instruments & Supplies
- Exchange
- NYQ
- Country
- Canada
- Employees
- 13,500